Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Danish diabetes-drug maker Novo Nordisk (NYSE:NVO) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Novo Nordisk's business and see what CAPS investors are saying about the stock right now.

Novo Nordisk facts

Headquarters (founded)

Bagsvaerd, Denmark (1925)

Market Cap

$29.62 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$8.28 billion

Management

CEO Lars Sorensen (since 2000)

CFO Jesper Brandgaard (since 2000)

Return on Equity (average, last three years)

26.4%

Competitors

Eli Lilly (NYSE:LLY)

Sanofi-Aventis (NYSE:SNY)

Merck (NYSE:MRK)

CAPS members bullish on NVO also bullish on

Johnson & Johnson (NYSE:JNJ)

General Electric (NYSE:GE)

CAPS members bearish on NVO also bearish on

3M (NYSE:MMM)

Sources: Capital IQ (a division of Standard & Poor's), and Motley Fool CAPS.

Over on CAPS, 408 of the 421 members who have rated Novo Nordisk -- or 97% -- believe the stock will outperform the S&P 500 going forward. These bulls include Tuusa and Turbolover.

In November, Tuusa tapped Novo Nordisk as a leader in the war on diabetes:

With an ever increasing number of people becoming diabetic, this company is in a very good position to have an impact. Diabetes is a worldwide issue that will continue to grow (albeit unfortunately) into the future. Novo Nordisk is set as a solid foundation for future growth.

In a pitch from last week, Turbolover shares some firsthand insight into the company's brand-power and potential:

This one falls under the Fool Rule of investing in what you know. Sadly, diabetes is a growth industry, and Novo Nordisk has great name recognition. When I was diagnosed with type II diabetes, I instantly recalled the Novo Nordisk commercials from [National Public Radio].

Most diabetes related companies seem to focus on delivery systems for insulin. With Type II diabetes rates skyrocketing, current research will pay off in the long term.

My endocrinologist, who is a researcher, told me about a movement to LOWER the blood sugar levels considered to be diabetic. This would cast a wider net and a substantially higher percentage of the population would then require treatment.

What do you think about Novo Nordisk, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Novo Nordisk is a Motley Fool Global Gains recommendation, Johnson & Johnson is a choice of Income Investor, and 3M is an Inside Value selection. The Fool's disclosure policy always gets a perfect score.